APA (7th ed.) Citation

A, K., S, A., G, L., EA, C., & D, A. (2022). Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. JAMA network open, 5(6), e2216199. https://doi.org/10.1001/jamanetworkopen.2022.16199

Chicago Style (17th ed.) Citation

A, Klein-Brill, Amar-Farkash S, Lawrence G, Collisson EA, and Aran D. "Comparison of FOLFIRINOX Vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma." JAMA Network Open 5, no. 6 (2022): e2216199. https://doi.org/10.1001/jamanetworkopen.2022.16199.

MLA (9th ed.) Citation

A, Klein-Brill, et al. "Comparison of FOLFIRINOX Vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma." JAMA Network Open, vol. 5, no. 6, 2022, p. e2216199, https://doi.org/10.1001/jamanetworkopen.2022.16199.